Core Viewpoint - The newly listed stock, Beixin Life (688712), has experienced significant price declines shortly after its IPO, raising concerns about its performance and the potential for investor losses [1][11]. Company Overview - Beixin Life focuses on innovative medical devices for precise diagnosis and treatment of cardiovascular diseases, being the first domestic company to offer both IVUS (Intravascular Ultrasound) and FFR (Fractional Flow Reserve) systems, thus filling a domestic gap and reducing reliance on imports [3]. Financial Performance - The company has reported continuous losses over the past three years, with revenues of 92.45 million yuan in 2022, projected to increase to 316.6 million yuan by 2024. However, net losses are expected to decrease from 290 million yuan in 2022 to 43.6 million yuan in 2024, totaling approximately 460 million yuan in losses over the three years [4]. Underwriting and Fundraising - The underwriting firm for Beixin Life is China International Capital Corporation (CICC), which planned to raise a total of 999 million yuan. The funds are allocated for the construction of a medical device industrialization base (382 million yuan), R&D projects (470 million yuan), and working capital (100 million yuan) [6]. Stock Performance - Beixin Life's stock opened at 49.64 yuan on its first trading day, marking a 183.33% increase, but has since fallen for six consecutive days, closing at 39.48 yuan, representing a decline of over 29% from its peak [8][9]. Investor Sentiment - Many investors who bought shares at the initial high are now facing significant losses, with sentiments expressed in forums indicating frustration and disappointment, suggesting that the IPO may have been more about capitalizing on the company than about genuine investment opportunities [11][13].

近日，在上海圆满落幕的 CFS 第十四届财经峰会暨 2025 新质生产力企业家大会上，汇聚了来自政界、商界、学 界的精英，共同探讨全球经济新变局下的发展路径。在此次峰会上，深圳北芯生命科技股份有限公司（以下简 称"北芯"）凭借在智能化心血管精准介入解决方案领域的卓越科技实力与创新突破，脱颖而出，荣获"2025杰出医 疗科技创新奖"。值得一提的是，这已经是北芯连续六年在财经峰会中揽获殊荣。这一荣誉不仅体现了业界对北芯 技术实力的高度认可，更肯定了其在推动中国高性能创新医疗（002173）器械产业形成全球竞争力、助力经济韧 性建设进程中发挥的积极作用。 过去一年，北芯以"技术破壁者"的姿态，在心血管精准介入领域掀起新一轮创新浪潮，不断推出行业领先的产 品，进一步丰富了其智能化心血管精准介入解决方案，为中国高性能医疗器械产业发展持续注入动能。 发挥全球影响，迈向世界级医疗科技企业 中国高端医疗器械在国际舞台的影响力正持续攀升——从全球产业链的参与者蜕变为规则制定者。在这一历史性 跃迁中，北芯的成长轨迹堪称典范：这家企业用十年时间，用多项硬核创新重新定义了"中国智造"的含金量，其 发展路径恰是中国医疗器械产业从"跟跑 ...

3月31日，深圳北芯生命科技股份有限公司(Insight Lifetech)更新招股书，财务数据更新至2024年12月31 日。 此外，经营活动产生的现金流量净额于2024年转正，达2990.72万元，标志其核心业务具备自我"造 血"能力、业务内生增长实现正循环，财务抗风险能力增强；与此同时，2024年，北芯销售费用率、管 理费用率分别下降约21个百分点、26个百分点，体现经营效率提升。 国产龙头地位稳固，创新驱动增长 作为国产心血管精准介入器械领域的领军企业，北芯在核心产品线持续巩固市场优势。其自主研发的 IVUS(血管内超声)系统凭借"60MHz高清成像、高速回撤、智能化操作"等特性，在国产市场中占据重要 地位，并成为首个获批欧盟MDR认证的国产IVUS系统，进军国际市场。该产品自2022年获批上市以 来，2022年、2023年、2024年销售额分别为935.51万元、9,708.59万元、21,712.94万元，截至2024年 底，已覆盖国内约1000家医院，市场份额快速攀升。 另一核心产品FFR(血流储备分数)系统作为国内首个获批的金标准FFR产品，2020年上市时，国家药监 局官网评价其"属于国际领 ...